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Abstract
Aims: The objectives of this study are to identify the proportion and characteristics of 
people with type 1 and 2 diabetes treated in primary, specialist and shared care and to 
identify the proportion of persons with type 2 diabetes reaching HbA1c treatment tar-
gets and the clinical risk factors and general practitioner and practice characteristics 
associated with treatment in specialist care.
Methods: Population- based cross- sectional study including all adults ≥18 years di-
agnosed with diabetes in primary and specialist care in Salten, Norway. We used 
multivariable mixed- effects logistic regression models with level of care as outcome 
variable and population, general practitioner, and practice characteristics as exposure 
variables.
Results: Of 2704 people with type 2 diabetes, 13.5% were treated in shared care 
and 2.1% in specialist care only. Of 305 people with type 1 diabetes, 14.4% received 
treatment in primary care only. The HbA1c treatment target of 53 mmol/mol (7.0%) 
was reached by 67.3% of people with type 2 diabetes in primary care versus 30.4% in 
specialist care. HbA1c, use of insulin, coronary heart disease, retinopathy and urban 
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1 |  INTRODUCTION
The prevalence of diabetes is increasing worldwide and so 
is the proportion of people living with diabetes and vascu-
lar complications and the overall healthcare related costs of 
the disease.1 The goal of diabetes care is to reduce vascular 
complications and prolong high quality of life.2 Several stud-
ies have shown the importance of glucose- lowering therapy, 
blood pressure and lipid control in reducing the risk of car-
diovascular outcomes.3 Preventing or postponing vascular 
complications will reduce both the individual and the societal 
burden of the disease.
Accordingly, this calls for an efficient, evidence- based 
and cost- effective organization of diabetes healthcare. The 
World Health Organization supports the trend of chronic care 
shifting from the secondary to the primary healthcare sector 
because a strong primary care service is essential to meet the 
observed worldwide challenges related to diabetes.4 Finding 
the right balance between levels of care and identifying indi-
viduals who may benefit from treatment in specialist care is 
essential. This will also facilitate optimal utilization of avail-
able healthcare resources.
The pathophysiology, aetiology and treatment of type 2 
diabetes (T2D) and type 1 diabetes (T1D) differ. Optimal care 
should integrate individual, medication and provider factors.5 
As there are no international guidelines on allocation to pri-
mary or specialist care of persons with T2D, both guidelines 
and organization differ between countries.6,7 The Norwegian 
diabetes guidelines state that individuals with T1D should be 
treated in specialist care. Individuals with complicated T2D 
should be referred to specialist care. Studies on people with 
T2D have shown that socio- economic status (SES) influ-
ences follow- up in many ways, including individual capabil-
ities, health- related behaviours, access to care, processes of 
care and risk of complications.8,9
Given the two levels of care (primary and specialist care) 
in people with T2D, it is important to evaluate the current 
patterns of management of the population of people with di-
abetes, as well as the characteristics of general practitioners 
(GPs) and GP practices associated with treatment levels.
We hypothesized that people with T2D treated in special-
ist care have more complex diseases with less achievement of 
treatment targets and more vascular complications than those 
treated in primary care only. Thus, we aimed to identify the 
proportion and characteristics of people with T2D and T1D 
treated in primary, shared and specialist care as well as the 
proportion of people with T2D reaching HbA1c treatment 
targets. Furthermore, our aim was to identify clinical risk 
factors, GP and practice characteristics associated with T2D 
treatment in specialist care.
2 |  RESEARCH DESIGN AND 
METHODS
2.1 | Study design and setting
We used data from the Norwegian cross- sectional study 
ROSA 4 including all adults (≥18  years) with T1D and 
T2D living in the Salten region as at 31 December 2014.10,11 
The ROSA 4 study was approved by the Regional Ethical 
Committee West (REK 2014/1374, REK Vest), with 
practice location were positively associated with treatment in specialist care. General 
practitioners’ use of a structured form and a diabetes nurse were negatively associated 
with specialist care.
Conclusions: Of people with type 2 diabetes, 16% were treated in specialist care. 
They had higher HbA1c and more vascular complications, as expected from priority 
guidelines. The use of a structured diabetes form and diabetes nurses seem to support 
type 2 diabetes follow- up in primary care.
What's new?
• The increasing prevalence of diabetes calls for an optimal utilization of healthcare 
resources.
• Individuals with type 2 diabetes treated in specialist care had higher HbA1c and 
more vascular complications than those treated in primary care only and were thus 
rightly allocated. General practitioner's (GP's) use of a structured diabetes form and 
diabetes nurses were negatively associated with treatment in specialist care.
• The use of structured diabetes forms and diabetes nurses in primary care may re-
duce the workload in specialist care.
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permission to collect data without written consent from all 
individuals with diabetes visiting primary care. Data on in-
dividuals visiting specialist care were collected in those con-
senting to send their data to the Norwegian Adult Diabetes 
Registry.
All residents in Norway have equal access to primary and 
specialist healthcare services free of charge once their own 
contribution to medical services has exceeded the annual 
limit (approximately 233 EUR in 2014). All residents are as-
signed to one GP, who cares for a maximum of 2500 individ-
uals. The GP acts as a gatekeeper to specialist healthcare as 
specialists cannot see patients without referral.
Norwegian diabetes guidelines state that individuals with 
T1D ought to be treated in specialist care with individual-
ized follow- up and at least one annual consultation.12 In most 
people with T2D, cost- effective diabetes care can be pro-
vided in a primary care setting,13- 15 with at least one visit 
per year. GPs can use a software tool (Noklus diabetes ap-
plication) that lists recommended tasks in the annual review 
and allows the performance of these tasks to be reported to 
the Norwegian Adult Diabetes Registry. Additional support 
from specialist care is recommended in individuals with poor 
glycaemic control, severe diabetes complications or compli-
cating co- morbidities.12 The Priority Guideline for Diabetes 
in the Specialist Health Service covers rights and deadlines 
for assessment of referrals to the specialist health service 
and ensures equality in clinical practice.16 People with T2D 
without severe vascular complications or co- morbidities and 
reaching treatment targets are generally returned to primary 
care.16 Diabetes nurses in Norway have additional education, 
some at master level, enabling them to independently provide 
lifestyle advice, educate on the use of insulin and contribute 
to better diabetes management.
Salten is a geographical area in Norway, both urban and 
rural, with a population of 80 338, 83 GPs and one diabetes 
outpatient clinic (i.e., diabetes specialist care) but no private 
diabetologists as of 31 December 2014. The total prevalence 
of diagnosed diabetes in Salten was 3.8% in 2014, 3.4% for 
T2D and 0.45% for T1D.10 As a result of a regional diabetes 
action plan, there has been a close cooperation between di-
abetes specialist care and GPs in this region during the last 
20 years.
2.2 | Population
The study population covered all individuals registered with 
T2D and T1D visiting primary care and all consenting indi-
viduals with T2D and T1D visiting the diabetes outpatient 
clinic (n = 682 out of 690 [98.8%]) between 1 January 2012 
and 31 December 2014. After excluding individuals with 
gestational and other types of diabetes (maturity- onset dia-
betes of the young [MODY] or pancreatitis, n  =  18) from 
the total diabetes sample (n = 3027), the final study sample 
included 3009 individuals: 2704 with T2D and 305 with T1D 
(Figure 1). Individuals registered with primary care follow-
 up had visited their GP for diabetes and were not treated in 
specialist care during the study period. Individuals registered 
with specialist care had one or more visits at the diabetes out-
patient clinic. This group included individuals with specialist 
care only and individuals with consultations in both primary 
and specialist care, defined as shared care. All GPs and GP 
practices in the area were invited, and all GPs agreed to par-
ticipate in the study.
2.3 | Data sources
In primary care, all individuals ≥18 years with diabetes (T89 
and T90 in the International Classification of Primary Care) 
registered in electronic medical records from 1 January 2012 
to 31 December 2014 were included. Predefined data were 
extracted according to a protocol.11 Data quality was ensured 
by an experienced research nurse visiting all GPs to verify 
data and search for missing data in the electronic medical re-
cords, including reports from specialists. The search had been 
F I G U R E  1  Study population according 
to level of care; primary, specialist or shared 
care
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tested in a pilot ensuring the accuracy of key search words 
used. Data from the only outpatient clinic were obtained 
from the Norwegian Adult Diabetes Registry and included 
all consenting individuals treated at the clinic. Information 
about education level and country of birth was obtained from 
‘Statistics Norway’ and linked to the electronic health re-
cords. Information about the GPs and GP practices was col-
lected by a questionnaire, with 96.3% response rate.
2.4 | Variables
A detailed description of variables used in the present study 
has been published.11 In short, the following population vari-
ables were registered: sex, age, diabetes duration, body mass 
index (BMI), medication, HbA1c, blood pressure (BP), total 
cholesterol, low- density lipoprotein (LDL) cholesterol, cre-
atinine and vascular complications (retinopathy, nephropa-
thy, neuropathy, foot ulcer, lower limb amputation, coronary 
heart disease [CHD], stroke, percutaneous transluminal an-
gioplasty/arterial surgery). Serum creatinine was measured in 
µmol/L, and estimated glomerular filtration rate (eGFR) was 
calculated using the CKD- EPI equation. We used the last reg-
istered value within 3 years for HbA1c, BP, lipids and eGFR. 
BP values in primary care were registered within 15 months 
(Table S1). We used the most adverse outcome or complica-
tion in the analyses if registrations in primary and special-
ist care differed in individuals with shared care. Medications 
were extracted from the GP's electronic prescription records 
from 1 October 2013 to 31 December 2014, and from GP 
and specialist database registrations. The classification of 
diabetes type was based on the doctor's clinical diagnoses, 
supplemented by measurements of beta cell antibodies and 
C- peptide when indicated.10
Variables regarding GPs included sex, age, medical ed-
ucation in Norway (yes/no), specialist status, workload de-
fined as number of people on the list, number of individuals 
with T2D listed and the use of a national structured electronic 
diabetes form with an annual review template supplying data 
to the Norwegian Adult Diabetes Registry. Practice variables 
included location (urban/rural) and diabetes nurse employed. 
Urban/rural status was defined as living in the only city 
(Bodø) versus small towns or rural areas.
Treatment targets were based on the key recommenda-
tions in the Norwegian diabetes guidelines from 2009 12 : 
HbA1c ≤53 mmol/mol (7.0%), intervention threshold for BP 
>140/85 mmHg with treatment target ≤135/80 mmHg, LDL 
cholesterol ≤3.5 mmol/L without lipid lowering therapy and 
≤1.8 mmol/L with and ≤2.5 mmol/L without known CHD.
Education was categorized as: (1) pre- primary and pri-
mary education (completion of compulsory school) or less 
(≤10  years), (2) secondary education (high school 11– 
13 years) and (3) tertiary education (university >13 years).
3 |  STATISTICAL ANALYSES
Descriptive statistics are presented as frequencies and per-
centages (categorical variables), means with standard devia-
tions or medians with interquartile range (IQR) (continuous 
variables). Nephropathy was categorized for descriptive pur-
poses according to standard categorization (eGFR ≥60, 30– 
59 and <30 ml/min/1.73 m2).
We used multivariable mixed- effects logistic regression to 
analyse the odds of being treated in specialist care and popu-
lation, GP and practice characteristics as exposure variables. 
We ran separate models for each exposure variable. We ad-
justed for age, sex, diabetes duration and education as fixed 
effects in the models due to possible confounding between 
outcome and the different exposure variables. GP practice 
was included as a random effect in the models. BMI was not 
included in the models due to a high level of missing values. 
In the regression analyses, we excluded 56 (2.1%) individuals 
with T2D treated in specialist care only due to lack of infor-
mation on GP and practice characteristics and individuals not 
registered with a GP. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were presented for univariable and multivari-
able results.
All statistical analyses were performed using STATA/SE 
14 (StataCorp, LP).
4 |  RESULTS
4.1 | Population characteristics in primary, 
specialist and shared care
In individuals with T2D, 84.4% (n = 2283) were treated in 
primary care only, 2.1% (n = 56) in specialist care only and 
13.5% (n = 365) in shared care (Table 1). Individuals treated 
in primary care only had mean age 66.4 (SD =12.6) years, 
compared with 64.1 (SD =13.0) and 60.7 (SD =12.9) years 
in specialist and shared care, respectively. The proportion 
of men was 54.9%, 69.9% and 63.0% in primary, specialist 
and shared care, respectively. In primary care, 16.7% of in-
dividuals with T2D had university education, compared with 
28.6% and 20.8% in specialist and shared care, respectively. 
The prevalence of CHD was 23.1% in primary care, 40.0% in 
specialist care and 28.8% in shared care. For retinopathy, the 
prevalence was 7.6%, 44.8% and 29.4%, respectively.
In individuals with T1D, the majority were treated in 
specialist and shared care, but 14.4% (n = 44) were treated 
in primary care only (Table 2). Among those treated in pri-
mary care only, mean age was 51.4 (SD =18.3) years, com-
pared with 43.7 (SD =14.2) years in specialist care and 47.0 
(SD =15.7) years in shared care. Median diabetes duration 
was 16 (IQR: 7– 33), 25 (IQR: 14– 36) and 19 (IQR: 11– 28) 
years, respectively.
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T A B L E  1  Type 2 diabetes persons characteristics, cardiovascular risk factors, prescribed medication and vascular complications
Type 2 diabetes, n = 2704








Age (years), mean (SD) 2283 (100) 66.4 (12.6) 365 (100) 60.7 (12.9) 56 (100) 64.1 (13.0)
Men, n (%) 2283 (100) 1254 (54.9) 365 (100) 230 (63.0) 56 (100) 39 (69.9)
Diabetes duration (years), 
median (IQR)
2093 (91.7) 6 (3– 11) 365 (100) 12 (7– 17) 56 (100) 11 (7– 19)
Age at diagnosis (years), median 
(IQR)
2093 (91.7) 59 (51– 67) 365 (100) 48.0 (41– 56) 56 (100) 52.0 (42– 61)
BMI (kg/m2), mean (SD) 1142 (50.0) 30.1(5.9) 361 (98.9) 31.7 (6.1) 54 (96.4) 29.9 (5.8)
Education 2261 (99.0) — 361 (98.9) — 56 (100) — 
Primary school, n (%) — 829 (36.7) — 116 (32.1) — 11 (19.6)
High school/craftmanship, n (%) — 1054 (46.6) — 170 (47.1) — 29 (51.8)
University, n (%) — 378 (16.7) — 75 (20.8) — 16 (28.6)
Born outside Europe, n (%) 2283 (100) 71 (3.1) 365 (100) 7 (1.9) 56 (100) 3 (5.4)
Cardiovascular risk factors
HbA1c, %, mean (SD) 2212 (96.9) 6.9 (1.1) 365 (100) 7.9 (1.4) 56 (100) 7.4 (1.3)
HbA1c, mmol/mol, mean (SD) 2212 (96.9) 51.4 (11.9) 365 (100) 62.4 (15.3) 56 (100) 57.6 (14.6)
Systolic blood pressure, mmHg, 
mean (SD)
1855 (81.3) 138 (16) 365 (100) 135 (15) 55 (98.2) 133 (15)
Diastolic blood pressure, mmHg, 
mean (SD)
1855 (81.3) 78 (10) 365 (100) 77 (10) 55 (98.2) 73 (11)
LDL cholesterol, mmol/L, mean 
(SD)
1987 (87.0) 2.8 (0.9) 365 (100) 2.7 (1.0) 54 (96.4) 2.6 (0.9)
With CHD, mmol/L, mean (SD) 469 (89.3a ) 2.5 (0.9) 105 (100a ) 2.4 (1.0) 14 (100a ) 2.3 (0.8)
No CHD, mmol/L, mean (SD) 1511 (86.3a ) 2.9 (0.9) 260 (100a ) 2.8 (0.9) 21 (100a ) 2.6 (1.0)
Prescribed lipid lowering agents, 
mmol/L
1204 (93.8a ) 2.6 (0.9) 277 (100a ) 2.5 (0.9) 31 (100a ) 2.4 (0.8)
No lipid lowering agents, 
mmol/L, mean (SD)
783 (78.4a ) 3.2 (0.9) 88 (100a ) 3.1 (0.9) 23 (92.0a ) 2.9 (0.9)
Prescribed medication
Antihypertensive agents, n (%) 2283 (100) 1645 (72.1) 365 (100) 277 (75.9) 56 (100) 37 (66.1)
Insulin, n (%) 2283 (100) 320 (14.0) 365 (100) 245 (67.1) 56 (100) 38 (67.9)
Lipid lowering medication, n 
(%)
2283 (100) 1284 (56.2) 365 (100) 277 (75.9) 56 (100) 31 (55.4)
Lipid lowering medication with 
CHD, n (%)
525 (100) 428 (81.5) 105 (100a ) 100 (95.2) 14 (100a ) 12 (85.7)
Lipid lowering medication with 
no CHD, n (%)
1750 (100) 850 (48.6) 260 (100a ) 177 (68.1) 21 (100a ) 11 (52.4)
Acetylsalicylic acid, n (%) 2283 (100) 844 (37.0) 365 (100) 162 (44.4) 56 (100) 18 (32.1)
Complications
Coronary heart disease, n (%) 2275 (99.6) 525 (23.1) 365 (100) 105 (28.8) 35 (62.5) 14 (40.0)
Stroke, n (%) 2281 (99.9) 186 (8.2) 365 (100) 19 (5.2) 35 (62.5) 3 (8.6)
PTA/arterial surgery, n (%) 2274 (99.6) 45 (2.0) 364 (99.7) 22 (6.0) 34 (60.7) 2 (5.9)
History of foot ulcer, n (%) 2278 (99.8) 27 (1.2) 365 (100) 30 (8.2) 34 (60.7) 6 (17.7)
Lower limb amputations, n (%) 2282 (100) 17 (0.7) 365 (100) 10 (2.7) 34 (60.7) 0 (0)
(Continues)
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4.2 | General practitioner and practice 
characteristics
For the 82 GPs included in the study, mean age was 44.7 
(SD =11.2) years, 58.1% were men and median years work-
ing as GP was 9 (IQR: 3– 24) (Table 3). A diabetes nurse was 
employed in 53.9% (n = 14) of the 27 practices.
4.3 | Attained treatment targets in 
primary and specialist care in people with T2D
In individuals with T2D, the HbA1c treatment target of 
53 mmol/mol (7.0%) was reached by 67.3% (95% CI [65.3, 
69.2]) in primary care versus 30.4% (95% CI [26.2, 35.0]) 
in specialist/shared care (Figure  2). In primary care, 6.7% 
(n = 148) had HbA1c values >69 mmol/mol (8.5%), of whom 
45.9% (n = 68) were younger than 60 years. There were no 
differences between levels of care in the proportion of indi-
viduals with T2D reaching treatment targets for BP and LDL 
cholesterol.
4.4 | Clinical and GP characteristics 
associated with treatment in specialist 
care setting
In adjusted analyses, HbA1c was positively associated with 
treatment in specialist care (OR =1.54, 95% CI [1.39, 1.71]), 
as the odds for specialist care treatment increased by 54% per 
one- unit increase in HbA1c (%) (Table  4). Diabetes- related 
complications such as CHD (OR  =1.99, 95% CI [1.47, 
2.68]), retinopathy (OR =2.78, 95% CI [1.97, 3.93]) and foot 
ulcer (OR =5.55, 95% CI [2.94, 10.48]) were also positively 
associated with treatment in specialist care. The use of a struc-
tured diabetes form and a diabetes nurse employed at the GP's 
office were both associated with reduced odds for treatment in 
specialist care (OR =0.53, 95% CI [0.40, 0.69] and OR =0.64, 
95% CI [0.50, 0.82], respectively). GP's age and urban loca-
tion were positively associated with treatment in specialist 
care (OR =1.01, 95% CI [1.00, 1.02] and OR =1.53, 95% CI 
[1.18, 1.98], respectively). In unadjusted analyses, education 
was not associated with treatment in specialist care.
5 |  DISCUSSION
The present study shows that 15.6% of people with T2D in 
Salten, Norway, were treated in specialist care (shared care 
or specialist care only). They were younger, more likely to 
be men and had higher HbA1c levels, less achievement of 
HbA1c treatment target and a higher prevalence of CHD, foot 
ulcer and retinopathy compared with individuals treated in 
primary care only. The GP's age and urban practice location 
were positively associated with treatment in specialist care, 
and the GP's use of a structured diabetes form and a diabe-
tes nurse employed at the GP practice were associated with 
reduced odds for treatment in specialist care. In people with 
T1D, 14.4% were treated in primary care only.
In accordance with our hypothesis, people with T2D 
treated in specialist care had more vascular complications 
and less achievement of treatment targets than those treated 
in primary care, despite their younger age, indicating a more 
complex disease.
Our findings are in line with previous studies on T2D re-
porting that specialists often see younger individuals that are 
more likely to be men with more vascular complications and 
higher HbA1c levels living in urban centres.
17- 19 Individuals 
Type 2 diabetes, n = 2704







Retinopathy, all, n (%) 1717 (75.2) 131 (7.6) 348 (95.3) 101 (29.4) 29 (51.8) 13 (44.8)
Untreated — 114 (6.6) — 73 (21.3) — 9 (31.0)
Treated — 17 (1.0) — 28 (8.2) — 4 (13.8)
Nephropathy, (eGFR, ml/
min/1.73 m2), n (%)
2167 (94.9) — 365 (100) — 56 (100) — 
 ≥60 — 1932 (89.2) — 332 (91.0) — 44 (78.6)
30– 59 — 209 (9.6) — 29 (8.0) — 9 (16.1)
<30 — 26 (1.2) — 4 (1.1) — 3 (5.4)
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; PTA, percutaneous transluminal angioplasty.
Data are presented as means with standard deviation (SD), median with interquartile range (IQR) or percent. Specialist care = Hospital diabetes outpatient clinic.
aPercentage of subpopulation with/without coronary heart disease (CHD) and prescribed/not prescribed lipid lowering medication.
T A B L E  1  (Continued)
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T A B L E  2  Type 1 diabetes persons characteristics, cardiovascular risk factors, prescribed medication and vascular complications
Type 1 diabetes, n = 305








Age (years), mean (SD) 44 (100) 51.4(18.3) 211 (100) 47.0 (15.7) 50 (100) 43.7 (14.2)
Men, n (%) 44 (100) 30 (68.2) 211 (100) 114 (54.0) 50 (100) 34 (68.0)
Diabetes duration (years), median 
(IQR)
40 (90.9) 16 (7– 33) 211 (100) 19 (11– 28) 50 (100) 25 (14– 36)
Age at diagnosis (years), median 
(IQR)
40 (90.9) 35 (16– 50) 211 (100) 23 (12– 38) 50 (100) 17 (11– 26)
BMI (kg/m2), mean (SD) 27 (61.4) 27.1 (5.0) 210 (99.5) 26.4 (4.6) 50 (100) 26.4 (4.2)
Education 43 (97.7) — 210 (99.5) — 50 (100) — 
Primary school, n (%) — 13 (30.2) — 55 (26.2) — 11 (22.0)
High school/craftmanship, n (%) — 20 (46.5) — 91 (43.3) — 23 (46.0)
University, n (%) — 10 (23.3) — 64 (30.5) — 16 (32.0)
Born outside Europe, n (%) 44 (100) 1 (2.3) 211 (100) 3 (1.4) 50 (100) 0 (0)
Cardiovascular risk factors
HbA1c, %, mean (SD) 34 (77.3) 7.8 (1.7) 211 (100) 8.3 (1.4) 50 (100) 7.9 (1.4)
HbA1c, mmol/mol, mean (SD) 34 (77.3) 61.8 (18.1) 211 (100) 67.2 (15.2) 50 (100) 63.4 (15.6)
Systolic blood pressure, mmHg, 
mean (SD)
30 (68.2) 134 (15) 211 (100) 126 (14) 50 (100) 128 (17)
Diastolic blood pressure, mmHg, 
mean (SD)
30 (68.2) 74 (11) 211 (100) 74 (9) 50 (100) 73 (10)
LDL cholesterol, mmol/L, mean 
(SD)
31 (70.5) 2.9 (1.1) 210 (99.5) 2.7 (0.8) 49 (98.0) 2.6 (0.6)
With CHD, mmol/L, mean (SD) 6 (100a ) 2.3 (0.7) 22 (100a ) 2.0 (0.7) 4 (100a ) 2.6 (1.0)
No CHD, mmol/L, mean (SD) 25 (65.8a ) 3.1 (1.1) 188 (99.5a ) 2.7 (0.8) 24 (100a ) 2.7 (0.5)
Prescribed lipid lowering agents, 
mmol/L
16 (94.1a ) 2.8 (1.1) 82 (100a ) 2.5 (1.0) 11 (100a ) 2.6 (0.6)
No lipid lowering agents, mmol/L, 
mean (SD)
15 (55.6a ) 3.1 (1.1) 128 (99.2a ) 2.8 (0.7) 38 (97.4a ) 2.7 (0.6)
Prescribed medication
Antihypertensive agents, n (%) 44 (100) 17 (38.6) 211 (100) 86 (40.8) 50 (100) 15 (30.0)
Lipid lowering medication, n (%) 44 (100) 17 (38.6) 211 (100) 82 (38.9) 50 (100) 11 (22.0)
Lipid lowering medication with 
CHD, n (%)
6 (100) 6 (100) 22 (100) 20 (90.9) 4 (100) 4 (100)
Lipid lowering medication with no 
CHD, n (%)
38 (100) 11 (29.0) 189 (100) 62 (32.8) 24 (100) 5 (20.8)
Acetylsalicylic acid, n (%) 44 (100) 11 (25.0) 211 (100) 41 (19.4) 50 (100) 6 (12.0)
Complications
Coronary heart disease, n (%) 44 (100) 6 (13.6) 211 (100) 22 (10.4) 28 (56.0) 4 (14.3)
Stroke, n (%) 44 (100) 4 (9.1) 211 (100) 8 (3.8) 28 (56.0) 0 (0)
PTA/arterial surgery, n (%) 44 (100) 3 (6.8) 211 (100) 5 (2.4) 28 (56.0) 1 (3.6)
History of foot ulcer, n (%) 44 (100) 0 (0) 211 (100) 17 (8.1) 28 (56.0) 2 (7.1)
Lower limb amputations, n (%) 44 (100) 0 (0) 211 (100) 6 (2.8) 28 (56.0) 0 (0)
Retinopathy, all, n (%) 34 (77.3) 14 (41.2) 203 (96.2) 103 (50.7) 30 (60.0) 34 (80.0)
(Continues)
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treated in specialist care are more likely to be monitored accord-
ing to guidelines, with achievement of adequate HbA1c levels 
19- 22 ; the last stands in contrast to our findings of higher HbA1c 
levels in specialist care. Whether follow- up in specialist care 
positively affects HbA1c, hypertension, vascular complications 
or improves survival is unclear, as results are conflicting.17,23- 26
In a recent Norwegian study on people with T2D, the GP's 
use of a structured diabetes form was associated with 23% 
higher odds of achieving the HbA1c treatment target and 17% 
higher odds of achieving LDL cholesterol target.27 In our study, 
the GP's use of a structured diabetes form and a diabetes nurse 
employed at the office were both associated with reduced odds 
for treatment in specialist care. This may indicate a more struc-
tured diabetes review and increased knowledge and competence 
in diabetes treatment, all leading to less need for referrals to 
specialist care. Whereas GP characteristics such as sex, special-
ist status and workload were not associated with treatment in 
specialist care, urban location was. This indicates geographical 
proximity to the specialist care to be of importance. The reason 
for this is unknown but could possibly be caused by short trans-
port distance to specialist care or patients’ preferences.
Previous studies in people with T2D have reported that 
SES influences follow- up at multiple levels, including access 
of care.8 In the present study, education was not associated 
with treatment in specialist care, indicating no differences in 
access to healthcare according to SES. However, only 91 pa-
tients treated in specialist care had university education.
According to Norwegian diabetes guidelines,12 all individ-
uals with T1D have the right to specialist care. Yet, our study 
surprisingly showed that 14.4% were treated in primary care 
only. A longitudinal cohort study from the UK including 113 
young people with T1D reported that 3% did not attend any 
clinic and 22% were cared for exclusively by their GPs at fol-
low- up.28 In a Finnish study, individuals with T1D received 
follow- up in primary care without compromising good quality 
and patient satisfaction.29 Others report associations between 
specialist care and lower HbA1c levels; however, individuals 
in specialist care also reported higher education and income 
levels.30 A higher proportion of diabetes duration spent in spe-
cialist care delayed the development of certain diabetes late 
complications.31 To our knowledge, large studies on level of 
care and disease severity in individuals with T1D are scarce.
The present study shows an overall adherence in the Salten 
region to the Norwegian diabetes guidelines recommendation 
Type 1 diabetes, n = 305







Untreated — 7 (20.6) — 71 (35.0) — 15 (50.0)
Treated — 7 (20.6) — 32 (15.8) — 9 (30.0)
Nephropathy, (eGFR, ml/
min/1.73 m2), n (%)
35 (79.5) — 210 (99.5) — 50 (100) — 
≥60 — 33 (94.3) — 205 (97.6) — 50 (100)
30– 59 — 2 (5.7) — 4 (1.9) — 0 (0)
<30 — 0 (0) — 1 (0.5) — 0 (0)
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; PTA, percutaneous transluminal angioplasty.
Data are presented as means with standard deviation (SD), median with interquartile range (IQR) or percent. Specialist care = Hospital diabetes outpatient clinic.
aPercentage of subpopulation with/without coronary heart disease (CHD) and prescribed/not prescribed lipid lowering medication.
T A B L E  2  (Continued)




General practitioners characteristics (n = 82)
Age (years), mean (SD) 76 44.7 (11.2)
Men, n (%) 74 43 (58.1)
Medical education in Norway, 
n (%)
75 54 (72.0)
Specialist in general practice, 
n (%)
75 37 (49.3)
Years working as GP, median 
(IQR)
72 9 (3– 24)
Workload (patients on list), 
median (IQR)
78 989 (826– 1224)
No. of people with T2D per 
GP, median (IQR)
82 31 (20– 46)
No. of people with shared care, 
median (IQR)
82 4 (2– 6)
General practitioner office characteristics (n = 27)
Diabetes nurse employed, n (%) 26 14 (53.9)
Urban location, n (%) 26 14 (53.9)
Abbreviations: GP, general practitioner; IQR, interquartile range; T2D, type 2 diabetes.
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that individuals with T2D and poor glycaemic control or com-
plicating co- morbidities should be treated in specialist care.12 
This may partly be a result of a longstanding, systematic co-
operation between the hospital and the GPs in the local mu-
nicipalities. Nevertheless, 46% of patients with HbA1c values 
>69 mmol/mol (8.5%) treated in primary care were younger 
than 60 years. Although factors such as the individuals’ prefer-
ences and medical or social disabilities can influence the deci-
sion of level of care, these findings are worrisome. Effective use 
of resources and a more efficient healthcare service will bene-
fit both individuals and the society. Individual assessments are 
necessary when deciding level of care. GPs may have a more 
holistic approach to diabetes care, whereas fragmented health-
care delivery can affect the individual's experience negatively.32
The strengths of the present study include a data col-
lection ensuring complete and accurate data on all adults 
with T2D and T1D and all GPs in a well- defined geograph-
ical area, resulting in an adequate sample size. Linkage to 
‘Statistics Norway’ ensured information on education level. 
Further, in Norway, individuals have equal access to health-
care, and the study was done in the absence of financial in-
centives related to pay- for- performance. Our study is limited 
by its cross- sectional design, as we do not have information 
on the development of risk profile over time, in particular not 
the risk profile at the time of referral and during treatment 
in specialist care. In addition, factors such as co- morbidity, 
the individual's preferences, frailty and social conditions 
may influence the decision to refer and care for people with 
T2D in specialist care, not shown in this study. Excluding 56 
individuals with T2D treated in specialist care only due to 
lack of information on GP and practice characteristics from 
the regression analyses may have introduced some selection 
bias. Salten is fairly representative of Norway, except for a 
lower proportion of immigrants born outside Norway than 
the Norwegian average in 2014 (7.1% vs. 12.4%). The study 
findings might be generalizable to other parts of Norway and 
possibly to countries with a similar system. Generalization of 
these results to other countries with a different organization 
of healthcare should be made with caution.
In conclusion, the present study shows that on the whole, 
people with T2D were appropriately allocated to primary and 
specialist care according to age, hyperglycaemia and vascular 
complications. However, surprisingly many individuals with 
T1D were treated exclusively in primary care. The use of a 
structured diabetes form and diabetes nurses may support 
T2D follow- up in primary care leading to better organiza-
tion of diabetes healthcare for the benefit of the individual. 
Further longitudinal studies on better risk stratification as a 
guide for allocation of individuals between primary and spe-
cialist care should be performed.
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